Teva Secures Rights to Launch Generic Viagra

Photo of Trey Thoelcke
By Trey Thoelcke Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Pfizer Inc.’s (NYSE: PFE) patent protecting popular erectile dysfunction drug Viagra from generic competition may not expire until April 2020, but Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has acquired rights to launch its generic version in the United States in December of 2017, or perhaps sooner.

Viagra is one of Pfizer’s best-selling drugs, generating about $1.2 billion in sales in the United States last year and more than $2 billion worldwide. Pfizer announced Tuesday that Teva Pharmaceuticals USA will pay an undisclosed royalty for a license to produce its copycat version of Viagra. The terms of the settlement agreement were largely confidential.

The two companies have come to terms after Pfizer sued Teva back in 2010 over its plans to introduce a generic version of Viagra. Teva argued that Pfizer’s U.S. patent on Viagra is invalid. The deal announced Tuesday is part of the settlement of the patent suit.

Viagra has the same active ingredient as Pfizer’s heart medication Revatio — sildenafil citrate. The patent on the active ingredient had already expired, but Pfizer received an additional patent on the use of the drug to treat erectile dysfunction, extending its exclusivity until April 2020. The validity of Pfizer’s patent was upheld by a federal judge in 2011.

In addition, Eli Lilly and Co.’s (NYSE: LLY) erectile dysfunction drug Cialis loses its patent protection in 2017. Drugmakers fight aggressively to protect patents because sales of their drugs typically plunge after cheaper, generic versions hit the market.

Shares of Pfizer and Teva were inactive in premarket trading Wednesday. The former closed at $30.14 Tuesday, in a 52-week range of $24.63 to $32.50. The latter closed at $39.84 in a 52-week range of $36.26 to $41.74.

Photo of Trey Thoelcke
About the Author Trey Thoelcke →

Trey has been an editor and author at 24/7 Wall St. for more than a decade, where he has published thousands of articles analyzing corporate earnings, dividend stocks, short interest, insider buying, private equity, and market trends. His comprehensive coverage spans the full spectrum of financial markets, from blue-chip stalwarts to emerging growth companies.

Beyond 24/7 Wall St., Trey has created and edited financial content for Benzinga and AOL's BloggingStocks, contributing additional hundreds of articles to the investment community. He previously oversaw the 24/7 Climate Insights site, managing editorial operations and content strategy, and currently oversees and creates content for My Investing News.

Trey's editorial expertise extends across multiple publishing environments. He served as production editor at Dearborn Financial Publishing and development editor at Kaplan, where he helped shape financial education materials. Earlier in his career, he worked as a writer-producer at SVE. His freelance editing portfolio includes work for prestigious clients such as Sage Publications, Rand McNally, the Institute for Supply Management, the American Library Association, Eggplant Literary Productions, and Spiegel.

Outside of financial journalism, Trey writes fiction and has been an active member of the writing community for years, overseeing a long-running critique group and moderating workshop sessions at regional conventions. He lives with his family in an old house in the Midwest.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618